Variable indoleamine 2,3‐dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Science"
DOI: 10.1111/cas.14195
Abstract: Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand‐1 (PD‐L1) is a well‐studied biomarker for response to anti–programmed death‐1 PD‐1 therapy in melanoma, its clinical relevance remains unclear. It has… read more here.
Keywords: acral mucosal; ido; indoleamine dioxygenase; expression ... See more keywords
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004879
Abstract: Background Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of… read more here.
Keywords: baseline; expression; resistant tumors; treatment ... See more keywords